Erin Kimbrel

Erin Kimbrel is Head of Cell and Gene Therapy Research at Astellas. In this role, she is responsible for driving discovery research through early process and analytical development towards IND filing of novel Cell and Gene Therapy (CGT) assets. Dr. Kimbrel has over two decades of experience in scientific research and drug discovery in regenerative medicine and molecular cancer biology. She has been with Astellas since 2016, holding previous roles of increasing responsibility and prior to that, several years in biotech with Ocata Therapeutics and Advanced Cell Technologies. She has been engaged in drug development across a broad range of therapeutic areas including ophthalmology, various immune-related indications, CNS, vascular and liver disease. Dr. Kimbrel is a former Fulbright Scholar and holds a Ph.D. in Pharmacology and Cancer Biology from Duke University. She completed post-doctoral training in Boston Massachusetts at the Dana-Farber Cancer Institute/Harvard Medical School and is a co-author on numerous publications and patents.